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A 61-year-old previously healthy male with a history of progressive fatigue, lower extremity edema, and
dyspnea for 4 months was hospitalized with pericardial and pleural effusions (Figure 1A, B). Lung,
pleural, and pericardial biopsies were consistent with Erdheim-Chester disease. He was treated with
systemic steroids, and ultimately tried on PEG-interferon. He deteriorated clinically and the disease
progressed to include CNS manifestations. Ultimately he was treated with Cladribine, at a dose 0.014 mg/
kg on day 1, followed by 0.09 mg/kg/day ¼ 6.4 mg IV for 6 additional days. He received 2 further cycles of
0.14 mg kg/day for 7 days (1 month apart). After 3 cycles he improved signiﬁcantly both clinically and
radiographically. Six months post-treatment objective testing showed improvement in cardiac, neuro-
logic, and pulmonary disease.
Erdheim Chester Disease (ECD) is a rare non Langerhans cell histiocytosis. Only several hundred cases
have been reported in the literature. Treatment for ECD is reserved for those with symptomatic disease,
asymptomatic CNS involvement, or evidence of organ dysfunction. There is no standard treatment
regimen: Current options include corticosteroids, Interferon alpha (IFN), systemic chemotherapy, and
radiation therapy. The occurrence of the V600EBRAF mutation in about 50% of patients can make these
patients amenable to targeted therapy with BRAF kinase inhibitors (e.g. Vemurafenib). More recently the
presence of N/KRAS, and PIK3CA mutations have provided further rational for targeted therapies. The
cytokine proﬁle in patients with ECD suggests monocyte activation cladribine, a purine analogue toxic to
monocytes, has also been studied as a treatment for ECD, especially in patients who test negative for the
BRAF mutation.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Erdheim Chester Disease (ECD) is a rare non-Langerhans cell
histiocytosis. Only several hundred cases have been reported in the
literature since it was ﬁrst described in 1930 [1]. It has been diag-
nosed in all age groups, more commonly in males between the 5th
and 7th decades of life [2]. While the pathophysiology is not
completely understood recent data shows that at least 50% of cases
harbor a BRAF mutation and that other cases may show ERK acti-
vation [1,3]. Treatment largely depends on the organ system (s)
involved and the extent of organ damage [4]. Recent advances in, MN 55905, USA.
deh).
Ltd. This is an open access article umutation analysis have identiﬁed possible targeted therapies for
treatment [5]. Cladribine is FDA approved for hairy cell leukemia
and has several other off-label uses, including Langerhans cell
Histiocytosis (LCH) and other lymphoproliferative disorders [6].
While it has been used in ECD with some promise reports of its use
are scant [1,7].
2. Case
A 61-year-old previously healthy male with a history of pro-
gressive fatigue, lower extremity edema, and dyspnea for 4 months
was hospitalized at an outside facility and diagnosed with a peri-
cardial effusion and bilateral pleural effusions (Fig. 1A and B). Lung,
pericardial, and pleural biopsies were consistent with Erdheim-
Chester disease (ECD) (Figs. 3 and 4). Treatment with prednisonender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Unenhanced thoracic CT prior to therapy initiation displayed in soft tissue (A) and lung (B) windows shows bilateral pleural effusions (B), a moderate-sized pericardial
effusion (*), and basal interlobular septal thickening (arrowheads). Enhanced thoracic CT displayed in soft tissue (C and lung (D) windows, performed approximately one year
following initiation of corticosteroid therapy, shows reduction in bilateral pleural effusions (B) and pericardial effusion (*), but with increasing interlobular septal thickening
(arrowheads). Perivascular soft tissue inﬁltration surrounding the descending thoracic aorta (arrows) is evident.
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ment allowing the patient to be discharged with supplemental
oxygen via nasal cannula.
He was referred to our institution 4 months later on 40 mg of
prednisone daily, attempts to taper prednisone had failed. He
complained of continued fatigue, progressive functional decline,
shortness of breath, and was dependent on supplemental oxygen.
An echocardiogram revealed cardiac muscle hypertrophy, and
elevated ﬁlling pressures in addition to small pericardial effusions
and adhesions without constrictive hemodynamics. Repeat
thoracic computed tomography (CT) (Fig. 1C and D) showed bilat-
eral pleural effusions, pericardial effusions, and diffuse interlobular
septal thickening. Pulmonary function tests (PFTs) showed a severe
restrictive defect, forced vital capacity (FVC) of 46% and diffusion
capacity for carbon monoxide (DLCO) 55%.
The patient's prednisone dose was increased to 60 mg/day
resulting in some improvement in symptoms; a second attempt to
taper prednisone over the course of a few months was unsuc-
cessful. While the abnormalities on thoracic CT remained stable
(Fig. 2A and B), PFTs revealed worsening restriction and worsening
of diffusion capacity (FVC decreased from 46% to 34%, and DCLO
55% to 36%). The tumor was negative for the BRAF mutation,
eliminating consideration of Vemurafenib (BRAF kinase inhibitor).
The patient was started on PEG interferon (IFN) (100/80 mcg sub-
cutaneously weekly), with reduced oxygen requirements and
improvement in overall strength after 10 weeks of therapy without
any undue toxicity. The prednisone dose was tapered to 9 mg per
day and his pulmonary function testing had improved. This clinical
improvement was transient and the patient developed worsening
symptoms after just a few months of therapy. Furthermore the
patient developed central nervous system (CNS) disease marked byprogressive neurological symptoms, including cognitive decline
and gait abnormalities. An MRI of the brain revealed T2 signal ab-
normalities in the cerebellum extending to the peduncles and 4th
ventricle, as well as in the pons and posterior midbrain. Cladribine
was started because of the neurologic disease progression, at a dose
of 0.014mg/kg on day 1, followed by 0.09mg/kg/day¼ 6.4mg IV for
6 additional days [2,7]. He received 2 further cycles of 0.14 mg kg/
day for 7 days (1 month apart). After 3 cycles he improved signif-
icantly both clinically and radiographically.
Six months post-treatment, objective testing showed improve-
ment in neurologic, cardiac, and pulmonary disease. The echocar-
diogram showed signiﬁcant improvement with stabilized systolic
function with an EF of 50%, a signiﬁcant improvement in diastolic
function, and a large improvement in right ventricular systolic
pressure. MRI brain revealed improved lesions in the posterior
fossa previously described. PFTs and ﬁndings on CT chest also
improved. (Fig. 2C and D).3. Discussion
Non-Langerhans histiocytoses are derived from the monocyte-
macrophage lineage. Clinical manifestations vary, and can involve
various organ systems [4,8], but the most common clinical pre-
sentations are bone pain, neurological features, diabetes insipidus,
and constitutional symptoms [8]. The long bones, heart, lungs,
central nervous system (CNS), skin, pituitary gland and orbits are
the most commonly involved [13]. The disease course can be
relatively benign with spontaneous remission, or rapidly progres-
sive and fatal. Prognosis is largely dependent on the number and
extent of organs involved, however CNS involvement is an inde-
pendent predictor of survival [8,9].
Fig. 2. Repeat enhanced thoracic CT prior to initiation of cladribine therapy, but following PEG interferon treatment, displayed in soft tissue (A) and lung (B) windows shows
resolution of pericardial ﬂuid but with development of pericardial and cardiac soft tissue inﬁltration (*); similarly, pleural liquid has resolved, but extensive pleural thickening (B)
has developed. Interlobular septal thickening (arrowheads) with patchy bilateral increased lung opacity and periaortic soft tissue inﬁltration (arrows) persist. Enhanced thoracic CT
displayed in soft tissue (C) and lung (D) windows 4 months following completion of 3 cycles of cladribine therapy shows persistent but decreased bilateral medial basal pleural
thickening (B) with persistent but slightly less pronounced bilateral interlobular septal thickening (arrowheads) and overall improved in bilateral lung opacity compared to (B).
Fig. 3. Wedge biopsy of lung, including pleura. There is both pleural and interlobular septal thickening (left panel, hematoxylin-eosin, x4), as a result of an accumulation of foamy
macrophages (right panel, hematoxylin-eosin, x400). These macrophages expressed CD68, and Factor XIIIa, but not CD1a, as is characteristic of Erdheim-Chester disease.
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ease, asymptomatic CNS involvement, or evidence of organ
dysfunction. While close monitoring has been recommended for
those without CNS involvement and no symptoms, the paucity of
data limits these recommendations [1]. There is no standard
treatment regimen. Current options include corticosteroids, inter-
feron alpha (IFN), systemic chemotherapy, and radiation therapy
[1]. ECD is thought to be a clonal disorder originating from the
monocytic myeloid lineage. The driving molecules appear to
involve the BRAF and NRAS signal pathways. The occurrence of the
V600EBRAF mutation in about 50% of patients can make these
patients amenable to targeted therapy with BRAF kinase inhibitors
(Vemurafenib) [1,10]. In addition, other mutations such as N/KRAS,and PIK3CA have provided further rational for targeted therapies
[5].
Systemic chemotherapy regimens have been studied in other
histiocytic disorders, such as LCH. Such therapies are considered for
patients who fail to respond to IFN or who develop intolerable side
effects. The most commonly used regimen is a 24-week treatment
consisting of vinblastine, etoposide, prednisone and 6-
mercaptopurine. The rationale behind these agents is lacking and
their use is largely empirical as these drugs were the only ones
available in the chemotherapeutic armamentarium when treat-
ment for this disease was ﬁrst reported. More recent literature
suggests that in addition to BRAF, there are other mutations that
can be amenable to targeted therapies; such as N/KRAS, and PIK3CA
Fig. 4. Thickened pericardium with inﬁltrate of histiocytes with both eosinophilic and
somewhat foamy cytoplasm.
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geted small molecules is lacking. A variety of other therapies have
been used in ECD, including alkylating chemotherapies, TNF in-
hibitors, inhibitors of BRAF, though reports of their efﬁcacy are
largely restricted to single patient case reports or very small case
series.
Cladribine (2-chloro-20-deoxy- b -D-adenosine, a.k.a. 2-CDA), is a
purine analogue toxic to monocytes, has also been studied as
treatment for ECD. The cytokine proﬁle in patients with ECD sug-
gests monocyte activation [11] and, given that tissue histiocytes
and monocytes have common progenitor cell origins, cladribine
could theoretically be an effective treatment option for ECD pa-
tients. Cladribine has been studied in a phase II clinical trial of 13
patients with adult LCH with good response. Patients received
0.14 mg/kg/day for 5 consecutive days every 4 weeks for a
maximum of 6 cycles. All patients attained complete response [6].
Our patient tolerated the treatment well and had signiﬁcant
improvement clinically and radiologically after just 3 cycles.
Although the overlap between LCH and ECD is not well understood
[1] the activity of cladribine against monocytes makes cladribine
therapy a reasonable option in ECD [7].
Cladribine as treatment for Erdheim-Chester disease has shown
promising results in case reports [7]. Our patient had a dramatic
improvement both clinically and on multiple organ imaging with
cladribine therapy, after failing to achieve a sustained therapeutic
response from numerous other treatment regimens. This case adds
further credence to the efﬁcacy of cladribine in the treatment for
ECD, but also that it can mitigate and resolve CNS, pulmonary and
cardiac manifestations of the disease. Cladribine penetrates the
blood brain barrier. Similar cases have been reported in patients
with progressive neurological manifestations who have tested
negative for the BRAF mutation but have responded to cladribine
after other therapies did not provide a sustained response [12].
Diffuse cardiac involvement has also been treated with cladribine
successfully [13].4. Conclusion
This case is one of several case reports suggesting that cladribine
is successful regardless of previous treatment regimens for adults
with ECD. The disease in our patient had failed to exhibit sustained
responses to several treatment regimens. After just 3 cycles of
cladribine the patient had signiﬁcant improvement which was
sustained at 15 months of followup. This response appears to come
with a relatively favorable toxicity proﬁle. Cladribine therapy does
confer long-term T cell depletion and, given its incorporation into
DNA, can be potentially mutagenic; thus only patients who are
symptomatic or have CNS involvement should receive this therapy,
and subsequently should be monitored closely for adverse effects.Conﬂict of interest
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